Methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter has been associated with better prognosis in newly diagnosed GBM patients undergoing radiotherapy and temozolomide (TMZ) maintenance treatment2. This evidence concerns the gene MGMT and glioblastoma.